Pharmamarketeer
Ascletis receives China NMPA approval, to begin phase IIa trial to treat RSV infection
onderzoek

Ascletis receives China NMPA approval to begin phase IIa trial of ASC10 to treat RSV infection

9 mei 2023
Pharma Biz

Ascletis receives China NMPA approval, to begin phase IIa trial to treat RSV infection

Ascletis Pharma Inc. announces that the China National Medical Products Administration (NMPA) has approved to conduct a phase IIa clinical trial for ASC10 to treat respiratory syncytial virus (RSV) infection. Based on available data, dosage of 800 mg ASC10, twice daily was selected to conduct a randomized, double-blind, placebo-controlled phase IIa study to evaluate the antiviral activity, safety, tolerability and pharmacokinetics of ASC10 tablets in patients with mild or moderate RSV infection.

Ook interessant voor je

Medhc-fases-banner
Advertentie(s)